Today AQILION AB announced that the extraordinary general meeting of the project company Adenovir Pharma AB resolved to liquidate the company. According to the decision, liquidation will begin on November 1, 2019. Adenovir Pharma developed an antiviral medication (APD-209) to treat and potentially even to prevent the contagious eye disease epidemic keratoconjunctivitis (EKC), which is […]
Aqilion is a Swedish life science company.
We believe the best source of new treatments comes from identifying, shaping and strengthening early drug innovation. We seek ideas that could potentially both improve patient quality of life and streamline health care.
We want to challenge and apply science in combination with creativity and entrepreneurship to maximize health care value for society.
Entries by Aqilion
Idag meddelar AQILION AB att vid en extra bolagsstämma i projektbolaget Adenovir Pharma AB togs beslutet att likvidera bolaget. Beslutet innebär att likvidationen inleds den 1 november 2019. Adenovir Pharma har utvecklat en antiviral läkemedelskandidat (APD-209) för behandling och potentiellt även förebyggande av den smittsamma ögonsjukdomen epidemisk keratokonjunktivit (EKC) som orsakas av virus. Fas 2-prövningen […]
Aqilion will participate at the partnering conference BIO-Europe on Nov 11-13 in Hamburg. Link to BIO-Europe
Aqilion identifies unique pharmaceutical projects at an early phase in the drug discovery process and develops them in preparation for clinical trials. The goal is to demonstrate the clinical and commercial potential of the medical innovation to attract industrial partners and buyers, who in turn have the capacity to continue clinical development and take the product to market.
The business model is based on involvement at an early stage and close collaboration with the innovator, regardless of whether the project is initiated by an external researcher, internal development project, or industrial partner.
Aqilion prefers projects aimed at niche markets. Specialty medications and orphan drugs are of particular interest.
Office Visiting Address
SE-252 20 Helsingborg